Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 10NIH 5INDUSTRY 3NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 20Lymphoid 5Other hematologic neoplasm 3Myeloid 1Dermatologic 1

Conditions

Sezary Syndrome 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma 1

Interventions

Interferon-alpha 6Radiosurgery 4Dacarbazine 4encorafenib 3binimetinib 3aldesleukin 3Radiotherapy 3Methotrexate 3Immunohistochemistry 3Gene Expression Profiling 3Filgrastim 3Etoposide 3Cyclophosphamide 3Cisplatin 3Watchful Waiting 2Vincristine 2Vinblastine 2Temozolomide 2Polymerase Chain Reaction 2Nivolumab 2Ipilimumab 2Introns 2Interferon alpha-2 2Immunologic Techniques 2Flow Cytometry 2Carboplatin 2trametinib 1tebentafusp 1sulforaphane 1sargramostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Lenalidomide × Dermatologic × Clear all
NCT01098656 2018-07-09

Lenalidomide Maintenance Post-debulking in Advanced CTCL

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Terminated
21 enrolled
DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡